Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality
- PMID: 18086836
- PMCID: PMC2258527
- DOI: 10.1128/AAC.01020-07
Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality
Abstract
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an emerging nosocomial pathogen. Little is known about its risk factors or mortality. We performed a case-case-control study to assess the risks for CRKP isolation and a retrospective cohort study to assess mortality in three groups of hospitalized adults: (i) patients from whom CRKP was isolated, (ii) patients from whom carbapenem-susceptible Klebsiella spp. (CSKS) were isolated, and (iii) controls from whom no Klebsiella spp. were isolated. After adjustment for length of stay (LOS), the demographics, comorbidities, and exposures of each case group were compared with those of the controls. Significant covariates were incorporated into LOS-adjusted multivariable models. In the mortality study, we evaluated the effect of CRKP on in-hospital death. There were 48 patients with CRKP isolation (21 died [44%]), 56 patients with CSKS isolation (7 died [12.5%]), and 59 controls (1 died [2%]). Independent risk factors for CRKP isolation were poor functional status (odds ratio [OR], 15.4; 95% confidence interval [CI], 4.0 to 58.6; P < 0.001); intensive care unit (ICU) stay (OR, 17.4; 95% CI, 1.5 to 201.9; P = 0.02); and receipt of antibiotics (OR, 4.4; 95% CI, 1.0 to 19.2; P = 0.05), particularly fluoroquinolones (OR, 7.2; 95% CI, 1.1 to 49.4; P = 0.04). CRKP was independently associated with death when patients with CRKP were compared with patients with CSKS (OR, 5.4; 95% CI, 1.7 to 17.1; P = 0.005) and with controls (OR, 6.7; 95% CI, 2.4 to 18.8; P < 0.001). After adjustment for the severity of illness, CRKP isolation remained predictive of death, albeit with a lower OR (for the CRKP group versus the CSKS group, OR, 3.9; 95% CI, 1.1 to 13.6; and P = 0.03; for the CRKP group versus the controls, OR, 5.0; 95% CI, 1.7 to 14.8; and P = 0.004). CRKP affects patients with poor functional status, an ICU stay, and antibiotic exposure and is an independent predictor of death.
Similar articles
-
Risk factors for the acquisition of nosocomial infection with carbapenem-resistant Klebsiella pneumoniae.South Med J. 2011 Feb;104(2):106-10. doi: 10.1097/SMJ.0b013e318206063d. South Med J. 2011. PMID: 21258230
-
Risk Factors for Carbapenem-resistant Klebsiella pneumoniae Infection and Mortality of Klebsiella pneumoniae Infection.Chin Med J (Engl). 2018 Jan 5;131(1):56-62. doi: 10.4103/0366-6999.221267. Chin Med J (Engl). 2018. PMID: 29271381 Free PMC article.
-
Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study.J Antimicrob Chemother. 2007 Nov;60(5):1124-30. doi: 10.1093/jac/dkm356. Epub 2007 Sep 20. J Antimicrob Chemother. 2007. PMID: 17884829
-
Risk factors for carbapenem-resistant Klebsiella pneumoniae infection relative to two types of control patients: a systematic review and meta-analysis.Antimicrob Resist Infect Control. 2020 Jan 31;9(1):23. doi: 10.1186/s13756-020-0686-0. Antimicrob Resist Infect Control. 2020. PMID: 32005246 Free PMC article.
-
Molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in Greece.Future Microbiol. 2016 Jun;11:809-23. doi: 10.2217/fmb-2016-0042. Epub 2016 May 20. Future Microbiol. 2016. PMID: 27206024 Review.
Cited by
-
Impact of a program combining pre-authorization requirement and post-prescription review of carbapenems: an interrupted time-series analysis.Eur J Clin Microbiol Infect Dis. 2013 Dec;32(12):1599-604. doi: 10.1007/s10096-013-1918-5. Epub 2013 Jul 10. Eur J Clin Microbiol Infect Dis. 2013. PMID: 23839593
-
Rapid and simultaneous detection of blaKPC and blaNDM by use of multiplex real-time PCR.J Clin Microbiol. 2013 Apr;51(4):1247-9. doi: 10.1128/JCM.03316-12. Epub 2013 Jan 16. J Clin Microbiol. 2013. PMID: 23325823 Free PMC article.
-
Nosocomial outbreak of Klebsiella pneumoniae carbapenemase-producing Klebsiella oxytoca in Austria.Antimicrob Agents Chemother. 2012 Apr;56(4):2158-61. doi: 10.1128/AAC.05440-11. Epub 2012 Jan 30. Antimicrob Agents Chemother. 2012. PMID: 22290949 Free PMC article.
-
Leveraging antimicrobial stewardship into improving rates of carbapenem-resistant Enterobacteriaceae.Virulence. 2017 May 19;8(4):383-390. doi: 10.1080/21505594.2016.1188234. Epub 2016 May 17. Virulence. 2017. PMID: 27187821 Free PMC article. Review.
-
Risk factors, molecular epidemiology and outcomes of ertapenem-resistant, carbapenem-susceptible Enterobacteriaceae: a case-case-control study.PLoS One. 2012;7(3):e34254. doi: 10.1371/journal.pone.0034254. Epub 2012 Mar 26. PLoS One. 2012. PMID: 22461908 Free PMC article.
References
-
- Ahmad, M., C. Urban, N. Mariano, P. A. Bradford, E. Calcagni, S. J. Projan, K. Bush, and J. J. Rahal. 1999. Clinical characteristics and molecular epidemiology associated with imipenem-resistant Klebsiella pneumoniae. Clin. Infect. Dis. 29:352-355. - PubMed
-
- Ben-Ami, R., M. J. Schwaber, S. Navon-Venezia, D. Schwartz, M. Giladi, I. Chmelnitsky, A. Leavitt, and Y. Carmeli. 2006. Influx of extended-spectrum beta-lactamase-producing Enterobacteriaceae into the hospital. Clin. Infect. Dis. 42:925-934. - PubMed
-
- Bradford, P. A., S. Bratu, C. Urban, M. Visalli, N. Mariano, D. Landman, J. J. Rahal, S. Brooks, S. Cebular, and J. Quale. 2004. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin. Infect. Dis. 39:55-60. - PubMed
-
- Bratu, S., S. Brooks, S. Burney, S. Kochar, J. Gupta, D. Landman, and J. Quale. 2007. Detection and spread of Escherichia coli possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York. Clin. Infect. Dis. 44:972-975. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
